Funding for this research was provided by:
Multiple Sclerosis Society of Canada
Text and Data Mining valid from 2019-12-01
Received: 18 October 2018
Accepted: 26 November 2019
First Online: 26 December 2019
Ethics approval and consent to participate
: The current study received research ethics approval from Sunnybrook Hospital and written consent was obtained from all participants.
: Not applicable.
: Bennis Pavisian declares no conflict of interest. Viral Patel declares no conflict of interest. Dr. Anthony Feinstein has served on scientific advisory boards for Merck Serono and Avanir Pharmaceuticals; has received speaker honoraria from Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, and Biogen Idec; servers on the editorial boards of <i>Multiple Sclerosis;</i> receives publishing royalties for <i>The Clinical Neuropsychiatry of Multiple Sclerosis</i> (Cambridge University Press, 2007); chairs the Medical Advisory Committee for the Multiple Sclerosis Society of Canada; conducts neuropsychiatric evaluation, cognitive testing, and brain imaging in neuropsychiatry in his clinical practice; and receives research support for the Canadian Institute of Health Research and the Multiple Sclerosis Society of Canada.